Literature DB >> 8390871

Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters.

K H Baumann1, L Kiesel, M Kaufmann, G Bastert, B Runnebaum.   

Abstract

Gonadotropin-releasing hormone analogs (GnRH-A) have been added to the armentarium in the therapy of hormone-dependent breast cancer in premenopausal women. The effect of chronic GnRH-A-treatment in premenopausal women is based on the suppression of the hypothalamus-pituitary-ovarian axis and the reduction of sex-steroid serum levels. In addition, a number of experimental and clinical data have been accumulated indicating a direct action of GnRH-A on breast cancer cells and tissue. In this study we analyzed 235 human breast cancer biopsies for specific GnRH-A-binding. We demonstrate high affinity GnRH-A binding sites in human breast cancer tissues. The evaluation of clinical data showed no correlation of the level of GnRH-A-binding with classical tumor parameters.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8390871     DOI： 10.1007/bf00662399

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


  46 in total

1.  Standards for the assessment of estrogen receptors in human breast cancer. Report of a workshop on September 29, 1972, at the Antoni van Leeuwenhoek-Huis, Amsterdam.

Authors: 
Journal:  Eur J Cancer       Date:  1973-05       Impact factor: 9.162

2.  Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists.

Authors:  K A Eidne; C A Flanagan; N S Harris; R P Millar
Journal:  J Clin Endocrinol Metab       Date:  1987-03       Impact factor: 5.958

3.  Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin.

Authors:  B Szende; A Zalatnai; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

4.  Zoladex plus tamoxifen versus Zoladex alone in pre- and peri-menopausal metastatic breast cancer.

Authors:  R I Nicholson; K J Walker; R A McClelland; A Dixon; J F Robertson; R W Blamey
Journal:  J Steroid Biochem Mol Biol       Date:  1990-12-20       Impact factor: 4.292

5.  Gonadotropin-releasing hormone analogues inhibit cell proliferation and activate signal transduction pathways in MDA-MB-231 human breast cancer cell line.

Authors:  G Kéri; A Balogh; B Szöke; I Teplán; O Csuka
Journal:  Tumour Biol       Date:  1991

Review 6.  Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies.

Authors:  A V Schally; G Srkalovic; B Szende; T W Redding; T Janaky; A Juhasz; E Korkut; R Z Cai; K Szepeshazi; S Radulovic
Journal:  J Steroid Biochem Mol Biol       Date:  1990-12-20       Impact factor: 4.292

7.  Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone.

Authors:  Y Sharoni; E Bosin; A Miinster; J Levy; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

8.  Corticotropin-releasing hormone, luteinizing hormone-releasing hormone, growth hormone-releasing hormone, and somatostatin-like immunoreactivities in biopsies from breast cancer patients.

Authors:  D R Ciocca; L A Puy; L C Fasoli; O Tello; J C Aznar; F E Gago; S I Papa; R Sonego
Journal:  Breast Cancer Res Treat       Date:  1990-05       Impact factor: 4.872

9.  Growth inhibition observed following administration of an LHRH agonist to a clonal variant of the MCF-7 breast cancer cell line is accompanied by an accumulation of cells in the G0/G1 phase of the cell cycle.

Authors:  P Mullen; W N Scott; W R Miller
Journal:  Br J Cancer       Date:  1991-06       Impact factor: 7.640

10.  Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630.

Authors:  P N Plowman; R I Nicholson; K J Walker
Journal:  Br J Cancer       Date:  1986-12       Impact factor: 7.640
View more
  16 in total

Review 1.  High-Throughput Approaches to the Development of Molecular Imaging Agents.

Authors:  Lina Y Hu; Kimberly A Kelly; Julie L Sutcliffe
Journal:  Mol Imaging Biol       Date:  2017-04       Impact factor: 3.488

2.  Influences of hydrocarbon linkers on the receptor binding affinities of gonadotropin-releasing hormone peptides.

Authors:  Haixun Guo; Helen Hathaway; Melanie E Royce; Eric R Prossnitz; Yubin Miao
Journal:  Bioorg Med Chem Lett       Date:  2013-08-23       Impact factor: 2.823

3.  GnRH receptors in human breast cancer and its contiguous not-involved breast tissue.

Authors:  A Paradiso; A Pezzetta; G Cellamare; F Schittulli; F Marzullo; S J Reshkin
Journal:  J Endocrinol Invest       Date:  2000-02       Impact factor: 4.256

4.  Introduction of D-phenylalanine enhanced the receptor binding affinities of gonadotropin-releasing hormone peptides.

Authors:  Jie Lu; Helen J Hathaway; Melanie E Royce; Eric R Prossnitz; Yubin Miao
Journal:  Bioorg Med Chem Lett       Date:  2014-01-06       Impact factor: 2.823

5.  Synthesis and evaluation of novel gonadotropin-releasing hormone receptor-targeting peptides.

Authors:  Haixun Guo; Jie Lu; Helen Hathaway; Melanie E Royce; Eric R Prossnitz; Yubin Miao
Journal:  Bioconjug Chem       Date:  2011-07-20       Impact factor: 4.774

6.  Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity.

Authors:  I Pályi; B Vincze; S Lovas; I Mezö; J Pató; A Kálnay; G Turi; D Gaál; R Mihalik; I Péter; I Teplán; R F Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

7.  Antitumour effect of a gonadotropin-releasing-hormone antagonist (MI-1544) and its conjugate on human breast cancer cells and their xenografts.

Authors:  B Vincze; I Pályi; D Daubner; A Kálnay; G Mezö; F Hudecz; M Szekerke; I Teplán; I Mezö
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

8.  Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo.

Authors:  Carsten Gründker; Crispin Föst; Stefanie Fister; Nadine Nolte; Andreas R Günthert; Günter Emons
Journal:  Breast Cancer Res       Date:  2010-07-14       Impact factor: 6.466

9.  Gonadotropin-releasing hormone agonists sensitize, and resensitize, prostate cancer cells to docetaxel in a p53-dependent manner.

Authors:  Roberta M Moretti; Marina Montagnani Marelli; Deanne M Taylor; Paolo G V Martini; Monica Marzagalli; Patrizia Limonta
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

10.  Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels.

Authors:  Petra Popovics; Andrew V Schally; Luca Szalontay; Norman L Block; Ferenc G Rick
Journal:  Oncotarget       Date:  2014-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.